A joint analysis of metabolomics and genetics of breast cancer.

A TDO2-AhR Signaling Axis Facilitates Anoikis Resistance and Metastasis in Triple-Negative Breast Cancer. Cancer Res (2015) 0.86

Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype. Oncotarget (2015) 0.84

Comprehensive profiling of amino acid response uncovers unique methionine-deprived response dependent on intact creatine biosynthesis. PLoS Genet (2015) 0.84

Alternative fuels for cancer cells. Cancer J (2015) 0.81

Metabolic Portraits of Breast Cancer by HR MAS MR Spectroscopy of Intact Tissue Samples. Metabolites (2017) 0.80

Cell competition with normal epithelial cells promotes apical extrusion of transformed cells through metabolic changes. Nat Cell Biol (2017) 0.80

Metabolic Signatures of Human Breast Cancer. Mol Cell Oncol (2015) 0.79

The space of enzyme regulation in HeLa cells can be inferred from its intracellular metabolome. Sci Rep (2016) 0.78

Combined Treatment of MCF-7 Cells with AICAR and Methotrexate, Arrests Cell Cycle and Reverses Warburg Metabolism through AMP-Activated Protein Kinase (AMPK) and FOXO1. PLoS One (2016) 0.78

Molecular portraits: the evolution of the concept of transcriptome-based cancer signatures. Brief Bioinform (2015) 0.77

A joint analysis of transcriptomic and metabolomic data uncovers enhanced enzyme-metabolite coupling in breast cancer. Sci Rep (2016) 0.77

Cystine addiction of triple-negative breast cancer associated with EMT augmented death signaling. Oncogene (2016) 0.77

Suppression of indoleamine-2,3-dioxygenase 1 expression by promoter hypermethylation in ER-positive breast cancer. Oncoimmunology (2017) 0.77

Cystine Deprivation Triggers Programmed Necrosis in VHL-Deficient Renal Cell Carcinomas. Cancer Res (2016) 0.77

An Aryl Hydrocarbon Receptor-Mediated Amplification Loop That Enforces Cell Migration in ER-/PR-/Her2- Human Breast Cancer Cells. Mol Pharmacol (2016) 0.77

Metabolic history impacts mammary tumor epithelial hierarchy and early drug response in mice. Endocr Relat Cancer (2016) 0.76

Metabolomic network analysis of estrogen-stimulated MCF-7 cells: a comparison of overrepresentation analysis, quantitative enrichment analysis and pathway analysis versus metabolite network analysis. Arch Toxicol (2016) 0.76

A plasma metabolomic signature discloses human breast cancer. Oncotarget (2017) 0.75

Impact of Freezing Delay Time on Tissue Samples for Metabolomic Studies. Front Oncol (2016) 0.75

On metabolic reprogramming and tumor biology: A comprehensive survey of metabolism in breast cancer. Oncotarget (2016) 0.75

(13)C and (15)N natural isotope abundance reflects breast cancer cell metabolism. Sci Rep (2016) 0.75

Collagen density regulates xenobiotic and hypoxic response of mammary epithelial cells. Environ Toxicol Pharmacol (2014) 0.75

Metabolomic Approaches in Cancer Epidemiology. Diseases (2015) 0.75

Short overview on metabolomics approach to study pathophysiology of oxidative stress in cancer. Redox Biol (2017) 0.75

Rapid determination of medulloblastoma subgroup affiliation with mass spectrometry using a handheld picosecond infrared laser desorption probe. Chem Sci (2017) 0.75

[Metabolome analysis of solid tumors]. Pathologe (2016) 0.75

Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A (1998) 192.97

Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A (2001) 132.88

Molecular portraits of human breast tumours. Nature (2000) 94.14

Statistical significance for genomewide studies. Proc Natl Acad Sci U S A (2003) 88.64

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A (2001) 71.82

Comprehensive molecular portraits of human breast tumours. Nature (2012) 47.39

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med (2004) 41.02

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature (2009) 19.65

Molecular definition of breast tumor heterogeneity. Cancer Cell (2007) 12.67

Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature (2009) 12.58

Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med (2009) 10.88

The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science (2010) 6.38

An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science (2013) 5.10

Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell (2012) 4.09

The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type. Cell Metab (2012) 3.81

Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells. Nature (2012) 3.77

Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. Proc Natl Acad Sci U S A (2011) 3.66

Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res (1999) 3.23

Systemic elevation of PTEN induces a tumor-suppressive metabolic state. Cell (2012) 2.39

Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth. Cancer Cell (2012) 2.39

Measurement of urinary D- and L-2-hydroxyglutarate enantiomers by stable-isotope-dilution liquid chromatography-tandem mass spectrometry after derivatization with diacetyl-L-tartaric anhydride. Clin Chem (2004) 2.35

MYC, metabolism, cell growth, and tumorigenesis. Cold Spring Harb Perspect Med (2013) 2.19

Alterations of choline phospholipid metabolism in ovarian tumor progression. Cancer Res (2005) 2.11

Novel theranostic opportunities offered by characterization of altered membrane lipid metabolism in breast cancer progression. Cancer Res (2011) 2.07

Comparison of HR MAS MR spectroscopic profiles of breast cancer tissue with clinical parameters. NMR Biomed (2006) 2.01

Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion. Cancer Res (2012) 1.98

Glutamine synthetase is a genetic determinant of cell type-specific glutamine independence in breast epithelia. PLoS Genet (2011) 1.90

MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis. J Clin Invest (2013) 1.89

Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. Breast Cancer Res Treat (2011) 1.89

BRCA1 induces antioxidant gene expression and resistance to oxidative stress. Cancer Res (2004) 1.69

A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen. Clin Cancer Res (2012) 1.52

Merging transcriptomics and metabolomics--advances in breast cancer profiling. BMC Cancer (2010) 1.41

Transport of gamma-glutamyl amino acids: role of glutathione and gamma-glutamyl transpeptidase. Proc Natl Acad Sci U S A (1979) 1.38

18F-fluorodeoxy-glucose positron emission tomography marks MYC-overexpressing human basal-like breast cancers. Cancer Res (2011) 1.36

BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival. J Exp Med (2013) 1.30

Increased serum kynurenine/tryptophan ratio correlates with disease progression in lung cancer. Lung Cancer (2009) 1.29

Analysis of tumor environmental response and oncogenic pathway activation identifies distinct basal and luminal features in HER2-related breast tumor subtypes. Breast Cancer Res (2011) 1.17

Impact of tumor microenvironment and epithelial phenotypes on metabolism in breast cancer. Clin Cancer Res (2012) 1.15

Regulation of lipid metabolism by p53 - fighting two villains with one sword. Trends Endocrinol Metab (2012) 1.15

Metabolic associations of reduced proliferation and oxidative stress in advanced breast cancer. Cancer Res (2012) 1.13

Remodeling of central metabolism in invasive breast cancer compared to normal breast tissue - a GC-TOFMS based metabolomics study. BMC Genomics (2012) 1.10

BRCA1 affects lipid synthesis through its interaction with acetyl-CoA carboxylase. J Biol Chem (2005) 1.08

Exon-centric regulation of pyruvate kinase M alternative splicing via mutually exclusive exons. J Mol Cell Biol (2011) 1.07

The metabolomic signature of malignant glioma reflects accelerated anabolic metabolism. Cancer Res (2012) 1.05

Method for lipidomic analysis: p53 expression modulation of sulfatide, ganglioside, and phospholipid composition of U87 MG glioblastoma cells. Anal Chem (2007) 1.02

Low concentrations of diindolylmethane, a metabolite of indole-3-carbinol, protect against oxidative stress in a BRCA1-dependent manner. Cancer Res (2009) 1.00

Miscoding properties of 2'-deoxyinosine, a nitric oxide-derived DNA Adduct, during translesion synthesis catalyzed by human DNA polymerases. J Mol Biol (2008) 1.00

Disruption of G1-phase phospholipid turnover by inhibition of Ca2+-independent phospholipase A2 induces a p53-dependent cell-cycle arrest in G1 phase. J Cell Sci (2006) 0.96

The emerging importance of α-L-fucose in human breast cancer: a review. Am J Transl Res (2011) 0.89

Metabolic phenotypes in triple-negative breast cancer. Tumour Biol (2013) 0.89

Tryptophan degradation in women with breast cancer: a pilot study. BMC Res Notes (2011) 0.87

Genome-wide analysis identifies a tumor suppressor role for aminoacylase 1 in iron-induced rat renal cell carcinoma. Carcinogenesis (2008) 0.87

Translocation of p53 to mitochondria is regulated by its lipid binding property to anionic phospholipids and it participates in cell death control. Neoplasia (2010) 0.86

Multiple metabolic alterations exist in mutant PI3K cancers, but only glucose is essential as a nutrient source. PLoS One (2012) 0.85

Mutational inactivation of aminoacylase-I in a small cell lung cancer cell line. Genes Chromosomes Cancer (1998) 0.82

Regulating cardiac energy metabolism and bioenergetics by targeting the DNA damage repair protein BRCA1. J Thorac Cardiovasc Surg (2013) 0.78

Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature (2005) 19.56

Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol (2004) 9.38

Gene expression predictors of breast cancer outcomes. Lancet (2003) 6.99

Diversity, topographic differentiation, and positional memory in human fibroblasts. Proc Natl Acad Sci U S A (2002) 6.98

A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. Am J Hum Genet (2007) 5.17

Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet (2010) 4.51

Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol (2008) 4.45

BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol (2002) 4.38

A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet (2009) 4.38

A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet (2010) 3.86

Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol (2006) 3.73

Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. Proc Natl Acad Sci U S A (2011) 3.66

Global control of cell-cycle transcription by coupled CDK and network oscillators. Nature (2008) 3.32

The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol (2009) 3.10

Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality. Sci Transl Med (2011) 2.97

Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci U S A (2003) 2.87

Integrated modeling of clinical and gene expression information for personalized prediction of disease outcomes. Proc Natl Acad Sci U S A (2004) 2.74

Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res (2005) 2.63

Genetic evidence and integration of various data sources for classifying uncertain variants into a single model. Hum Mutat (2008) 2.55

Acquired expression of periostin by human breast cancers promotes tumor angiogenesis through up-regulation of vascular endothelial growth factor receptor 2 expression. Mol Cell Biol (2004) 2.49

Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res (2005) 2.37

microRNA miR-144 modulates oxidative stress tolerance and associates with anemia severity in sickle cell disease. Blood (2010) 2.34

Gene expression phenotypes of atherosclerosis. Arterioscler Thromb Vasc Biol (2004) 2.23

Oncogenic properties of PPM1D located within a breast cancer amplification epicenter at 17q23. Nat Genet (2002) 2.23

Modeling cancer progression via pathway dependencies. PLoS Comput Biol (2008) 2.12

The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. Clin Cancer Res (2011) 2.09

The type III TGF-beta receptor suppresses breast cancer progression. J Clin Invest (2006) 2.06

Gender-specific methylation differences in relation to prenatal exposure to cigarette smoke. Gene (2011) 2.03

2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations. PLoS One (2011) 2.00

Pleiotrophin regulates the expansion and regeneration of hematopoietic stem cells. Nat Med (2010) 1.94

Validity of models for predicting BRCA1 and BRCA2 mutations. Ann Intern Med (2007) 1.94

Tagging single nucleotide polymorphisms in cell cycle control genes and susceptibility to invasive epithelial ovarian cancer. Cancer Res (2007) 1.92

Glutamine synthetase is a genetic determinant of cell type-specific glutamine independence in breast epithelia. PLoS Genet (2011) 1.90

Transcriptional programs following genetic alterations in p53, INK4A, and H-Ras genes along defined stages of malignant transformation. Cancer Res (2005) 1.86

Tumor vasculature is regulated by PHD2-mediated angiogenesis and bone marrow-derived cell recruitment. Cancer Cell (2009) 1.82

Genomic amplification and oncogenic properties of the KCNK9 potassium channel gene. Cancer Cell (2003) 1.76

Combined cDNA array comparative genomic hybridization and serial analysis of gene expression analysis of breast tumor progression. Cancer Res (2006) 1.74

Cyclin E overexpression in epithelial ovarian cancer characterizes an etiologic subgroup. Cancer Epidemiol Biomarkers Prev (2008) 1.73

High insulin-like growth factor-2 (IGF-2) gene expression is an independent predictor of poor survival for patients with advanced stage serous epithelial ovarian cancer. Gynecol Oncol (2005) 1.71

Gene expression patterns that characterize advanced stage serous ovarian cancers. J Soc Gynecol Investig (2004) 1.68

BAYESIAN MODEL SEARCH AND MULTILEVEL INFERENCE FOR SNP ASSOCIATION STUDIES. Ann Appl Stat (2010) 1.66

A small molecular weight catalytic metalloporphyrin antioxidant with superoxide dismutase (SOD) mimetic properties protects lungs from radiation-induced injury. Free Radic Biol Med (2002) 1.65

Prolonged culture of telomerase-immortalized human fibroblasts leads to a premalignant phenotype. Cancer Res (2003) 1.64

A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation. Genome Res (2012) 1.63

Aspirin exposure reveals novel genes associated with platelet function and cardiovascular events. J Am Coll Cardiol (2013) 1.61

The genomic analysis of lactic acidosis and acidosis response in human cancers. PLoS Genet (2008) 1.60

Methylation variation at IGF2 differentially methylated regions and maternal folic acid use before and during pregnancy. Epigenetics (2011) 1.60

The genomic analysis of erythrocyte microRNA expression in sickle cell diseases. PLoS One (2008) 1.60

Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer. Cancer Res (2009) 1.59

Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations. Cancer Res (2011) 1.58

Development of an ovarian cancer screening decision model that incorporates disease heterogeneity: implications for potential mortality reduction. Cancer (2010) 1.53

A manganese porphyrin superoxide dismutase mimetic enhances tumor radioresponsiveness. Int J Radiat Oncol Biol Phys (2005) 1.48

Evaluation of candidate stromal epithelial cross-talk genes identifies association between risk of serous ovarian cancer and TERT, a cancer susceptibility "hot-spot". PLoS Genet (2010) 1.47

Manganese superoxide dismutase, MnSOD and its mimics. Biochim Biophys Acta (2011) 1.46

Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas. Cancer Res (2012) 1.46

Hormonal risk factors for ovarian cancer in premenopausal and postmenopausal women. Am J Epidemiol (2008) 1.46

Novel tumor sampling strategies to enable microarray gene expression signatures in breast cancer: a study to determine feasibility and reproducibility in the context of clinical care. Breast Cancer Res Treat (2009) 1.46

Translocation of sickle cell erythrocyte microRNAs into Plasmodium falciparum inhibits parasite translation and contributes to malaria resistance. Cell Host Microbe (2012) 1.45

Age-specific differences in oncogenic pathway deregulation seen in human breast tumors. PLoS One (2008) 1.43

Frequent IGF2/H19 domain epigenetic alterations and elevated IGF2 expression in epithelial ovarian cancer. Mol Cancer Res (2006) 1.43

Association between invasive ovarian cancer susceptibility and 11 best candidate SNPs from breast cancer genome-wide association study. Hum Mol Genet (2009) 1.42

Design of Mn porphyrins for treating oxidative stress injuries and their redox-based regulation of cellular transcriptional activities. Amino Acids (2010) 1.41

p38gamma mitogen-activated protein kinase is a key regulator in skeletal muscle metabolic adaptation in mice. PLoS One (2009) 1.41

p53-dependent down-regulation of telomerase is mediated by p21waf1. J Biol Chem (2004) 1.39

Phase I trial of doxorubicin-containing low temperature sensitive liposomes in spontaneous canine tumors. Clin Cancer Res (2006) 1.37

Lactic acidosis triggers starvation response with paradoxical induction of TXNIP through MondoA. PLoS Genet (2010) 1.34

Analgesic drug use and risk of ovarian cancer. Epidemiology (2006) 1.33

Diverse functions of cationic Mn(III) N-substituted pyridylporphyrins, recognized as SOD mimics. Free Radic Biol Med (2011) 1.31

SOD therapeutics: latest insights into their structure-activity relationships and impact on the cellular redox-based signaling pathways. Antioxid Redox Signal (2013) 1.29

Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays. Am J Obstet Gynecol (2004) 1.29

Effect of hysterectomy with ovarian preservation on ovarian function. Obstet Gynecol (2011) 1.28

Association between DNA damage response and repair genes and risk of invasive serous ovarian cancer. PLoS One (2010) 1.28

Prediction and uncertainty in the analysis of gene expression profiles. In Silico Biol (2002) 1.27

Association of single nucleotide polymorphisms in glycosylation genes with risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev (2008) 1.26

Functional interaction between responses to lactic acidosis and hypoxia regulates genomic transcriptional outputs. Cancer Res (2011) 1.26

Depression in pregnancy, infant birth weight and DNA methylation of imprint regulatory elements. Epigenetics (2012) 1.25

Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer. J Clin Oncol (2005) 1.23

Urinary biomarkers of oxidative status in a clinical model of oxidative assault. Cancer Epidemiol Biomarkers Prev (2010) 1.21

Minimizing off-target effects by using diced siRNAs for RNA interference. J RNAi Gene Silencing (2006) 1.20

Urinary biomarkers of oxidative status. Clin Chim Acta (2012) 1.20

ISG15 as a novel tumor biomarker for drug sensitivity. Mol Cancer Ther (2008) 1.19

Flavin-dependent antioxidant properties of a new series of meso-N,N'-dialkyl-imidazolium substituted manganese(III) porphyrins. Biochem Pharmacol (2004) 1.19

Charting the landscape of tandem BRCT domain-mediated protein interactions. Sci Signal (2012) 1.19

Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer. Int J Cancer (2011) 1.17

Antiangiogenic action of redox-modulating Mn(III) meso-tetrakis(N-ethylpyridinium-2-yl)porphyrin, MnTE-2-PyP(5+), via suppression of oxidative stress in a mouse model of breast tumor. Free Radic Biol Med (2009) 1.17

Analysis of tumor environmental response and oncogenic pathway activation identifies distinct basal and luminal features in HER2-related breast tumor subtypes. Breast Cancer Res (2011) 1.17

Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome. Clin Cancer Res (2009) 1.16

Cell cycle progression in G1 and S phases is CCR4 dependent following ionizing radiation or replication stress in Saccharomyces cerevisiae. Eukaryot Cell (2004) 1.16

High throughput detection of M6P/IGF2R intronic hypermethylation and LOH in ovarian cancer. Nucleic Acids Res (2006) 1.16

Association of a genetic variation in a miR-191 binding site in MDM4 with risk of esophageal squamous cell carcinoma. PLoS One (2013) 1.16

Maspin expression in epithelial ovarian cancer and associations with poor prognosis: a Gynecologic Oncology Group study. Gynecol Oncol (2006) 1.15

Ovarian cancer tumor infiltrating T-regulatory (T(reg)) cells are associated with a metastatic phenotype. Gynecol Oncol (2009) 1.15